[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.119.60. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
The Cutting Edge
February 2002

Tazarotene Is an Effective Therapy for Elastosis Perforans Serpiginosa

Author Affiliations
 

GEORGE J.HRUZAMDDEE ANNAGLASERMDELAINESIEGFRIEDMD

Arch Dermatol. 2002;138(2):169-171. doi:10.1001/archderm.138.2.169
REPORT OF CASES
CASE 1

A 22-year-old woman presented with a 2-year history of an eruption on the anterior aspect of her neck and right arm that was relatively asymptomatic. She had a history of cystinuria, which had been treated with D-penicillamine for several years, but the D-penicillamine therapy had been discontinued 2 years before the onset of the eruption. A biopsy was performed approximately 1 year before her presentation to our institution. The biopsy specimen demonstrated clawlike downgrowths of epidermis surrounding collections of amorphous basophilic debris and hyperplastic elastic fibers. Many elastic fibers were noted to be pushing through epidermal channels (Figure 1), a finding that was consistent with the clinical diagnosis of elastosis perforans serpiginosa (EPS). The patient was treated unsuccessfully with several modalities in a sequential fashion, including liquid nitrogen cryotherapy monthly for 6 months, topical tretinoin gel nightly for 2 months, oral isotretinoin at dosages ranging from 40 to 60 mg/d for 15 weeks, and 2 sessions of carbon dioxide laser surgery. On physical examination, she was noted to have erythematous annular and arcuate keratotic plaques on the anterior aspect of her neck and right arm (Figure 2).

Figure 1.
Case 1. Biopsy specimen demonstrating transepidermal elimination of altered elastic fibers.

Case 1. Biopsy specimen demonstrating transepidermal elimination of altered elastic fibers.

Figure 2.
Patient 1 on presentation to our institution with erythematous annular plaques on her neck.

Patient 1 on presentation to our institution with erythematous annular plaques on her neck.

CASE 2

A 56-year-old woman was referred to our institution for evaluation of a prutitic "nonhealing scar" that had been present on the posterolateral aspect of the left side of her neck for 1 year. The lesions developed 1 month after a revised facial rhytidectomy scar revision. The patient had been treated with oral cephalexin for 2 weeks and topical erythromycin solution for several weeks, without improvement. Her medical history revealed that she had been treated with D-penicillamine for Wilson disease for more than 20 years. The D-penicillamine therapy had been discontinued 2 months before her presentation to our clinic.

Physical examination revealed multiple 2- to 7-mm crusted, erythematous, ulcerated papules and plaques with an arcuate configuration. These lesions were associated with a 6-cm-long scar on the posterolateral aspect of the left side of the neck.

A biopsy specimen demonstrated a central focus of pseudoepitheliomatous hyperplasia that appeared to be connected to the epidermis by a channel of epithelium. Adjacent inflammation with dermal necrosis, both within and surrounding the epithelia, was evident. An elastic stain demonstrated an increased concentration of elastic fibers in the middermis extending to the epidermis. Many of the elastic fibers appeared clumped and thickened.

The patient was treated unsuccessfully with cryotherapy approximately 6 times; high-potency topical corticosteroids, including clobetasol and halobetasol, for 6 weeks; topical 0.1% tretinoin cream and topical 0.05% tretinoin solution for about 2 months each; and several intralesional injections of triamcinolone acetonide (4 mg/mL).

THERAPEUTIC CHALLENGE

Multiple therapies have been reported to be effective in the management of EPS. However, none has been universally accepted as the treatment of choice. Reported effective treatments include liquid nitrogen cryotherapy1 and oral isotretinoin therapy.2 Our patients were previously treated with many modalities, without success; therefore, topical tazarotene therapy was initiated.

SOLUTION

Because multiple therapies had failed in both cases, the patients were offered a trial of 0.1% tazarotene gel. Both patients agreed and began using 0.1% tazarotene gel at bedtime. At the 1-month follow-up visits, their disease was somewhat improved. After 2 months of tazarotene therapy, the condition of patient 1 was greatly improved (Figure 3) and that of patient 2 was moderately improved. After 4 more weeks, patient 2 was almost free of active disease. Patient 2 then discontinued tazarotene therapy, and her disease flared. Other topical retinoid preparations were then tried, without improvement. Cryotherapy was tried a few more times, also without improvement, and the patient was finally re-treated with tazarotene, which flattened her lesions within 6 weeks. Patient 1 has tried to taper her usage of tazarotene but notices flares on discontinuation.

Figure 3.
Patient 1 after 2 months of treatment with 0.1% tazarotene gel.

Patient 1 after 2 months of treatment with 0.1% tazarotene gel.

The only adverse effect observed in both cases was mild irritation. However, the irritation subsided after a few weeks of therapy. Both patients continue to use tazarotene daily for intermittent courses when their disease flares.

COMMENT

Elastosis perforans serpiginosa is a disorder in which altered elastic fibers are recognized as foreign material and are extruded through the epidermis by transepidermal elimination. The result is a papular eruption that is usually arranged serpiginously, annularly, or arcuately. Many conditions are associated with EPS, including Down syndrome, Rothmund-Thomson syndrome, Ehler-Danlos syndrome, Marfan syndrome, osteogenesis imperfecta, and pseudoxanthoma elasticum. Also, patients treated with penicillamine are prone to develop EPS.3 Elastosis perforans serpiginosa usually occurs in young adults and shows a predilection for the head and neck.

Tazarotene is the first receptor-selective topical retinoid approved for the treatment of plaque psoriasis. It selectively targets the γ and β subtypes of retinoic acid receptors. Ninety percent of retinoid receptors in the skin are of the γ subtype. Hofmann et al4 reported tazarotene's effectiveness in the treatment of congenital ichthyoses in an open, intraindividually controlled, half-side investigation. Burkhart and Burkhart5 reported tazarotene's effectiveness in treating a patient with Darier disease who had responded poorly to other agents. One mechanism of action of tazarotene in psoriasis is thought to be attributable to the down-regulation of keratins 6, 10, and 16.4 Tazarotene also has a strong antiproliferative effect via the expression of 3 genes: tazarotene-induced genes 1 through 3.6 Tazarotene has a low systemic absorption and is rapidly metabolized and eliminated.7 The most common adverse effect reported is local irritation. To our knowledge, this is the first report of EPS being successfully treated with tazarotene. The mechanism of action of tazarotene in treating EPS is unknown. Tazarotene may have comedolytic properties that allow for the unplugging of transepidermal pores in this disease. Also, the blockage of retinoic acid receptors may play a role in decreasing the proliferation in EPS.

Back to top
Article Information

Accepted for publication July 19, 2001.

This study was presented as a poster at the annual meeting of the American Academy of Dermatology, San Francisco, Calif, March 10-15, 2000.

Corresponding author and reprints: Jeffrey P. Callen, MD, Department of Medicine, Division of Dermatology, University of Louisville, 310 E Broadway, Suite 2A, Louisville, KY 40202-1745 (e-mail: jefca@aol.com).

References
1.
Rosenblum  GA Liquid nitrogen cryotherapy in a case of elastosis perforans serpiginosa. J Am Acad Dermatol. 1983;8718- 721Article
2.
Ratnavel  RCNorris  PG Penicillamine-induced elastosis perforans serpiginosa treated successfully with isotretinoin. Dermatology. 1994;18981Article
3.
Mehregan  AH Elastosis perforans serpiginosa. Arch Dermatol. 1968;97381- 393Article
4.
Hofmann  BStege  HRuzicka  TLehmann  P Effect of topical tazarotene in the treatment of congenital ichthyoses. Br J Dermatol. 1999;141642- 646Article
5.
Burkhart  CGBurkhart  CN Tazarotene gel for Darier's disease. J Am Acad Dermatol. 1998;381001- 1002Article
6.
Nagpal  SPatel  SAsano  ATJohnson  ATDuvic  MChandraratna  RAS Tazarotene-induced gene 1 (TIG 1), a novel retinoic acid receptor–responsive gene in skin. J Invest Dermatol. 1996;106269- 274Article
7.
Foster  RHBrogden  RNBenfield  P Tazarotene. Drugs. 1998;55705- 711Article
×